Polypeptide No.	Starting Sequence	Epitope 1 Substitution	Epitope 2 Substitution	Epitope 3 Substitution
137	SEQ ID NO:7	T56K	None	K174R

12. The polypeptide of claim 11, selected from any one of Polypeptide Nos. 110, 112, 113, 116, 117, 118, 122, 127, 128 or 129.

13. A pharmaceutical composition comprising the polypeptide of any one of claims 1-12 and a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 13, wherein the composition is formulated for injection or infusion into the bloodstream of a patient.

15. The pharmaceutical composition of claim 13, wherein the composition is formulated for direct administration to the brain or CNS.

16. Use of the polypeptide of any one of claims 1-12 or the pharmaceutical composition of any one of claims 13-15 in the manufacture of a medicament for ~~A method of~~ reducing amyloid or tau protein aggregates in a patient in need thereof~~, comprising administering to the patient an effective amount of the polypeptide of any one of claims 1-12 or the pharmaceutical composition of any one of claims 13-15~~.

17. The ~~method~~ use of claim 16, wherein the patient is exhibiting symptoms of a neurodegenerative disease that is associated with the presence of amyloid or tau protein aggregates.

18. The ~~method~~ use of claim 16 or claim 17, wherein the patient is positive for the biomarker florbetapir when that biomarker is used as an imaging agent in positron emission tomography.

19. The use of ~~The method of~~ any one of claims 16-18, wherein the patient is suffering from a neurodegenerative disease selected from Alzheimer's disease, which includes early onset Alzheimer's disease, late onset Alzheimer's disease, and presymptomatic Alzheimer's disease, Parkinson's disease, SAA amyloidosis, cystatin C, hereditary Icelandic syndrome, senility, multiple myeloma, prion diseases including but not limited to kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker disease (GSS), fatal familial insomnia (FFI), scrapie, and bovine spongiform encephalitis (BSE); amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA1, SCA3, SCA6, or SCA7), Huntington disease, entatorubral-pallidoluysian atrophy, spinal and bulbar

muscular atrophy, hereditary cerebral amyloid angiopathy, familial amyloidosis, British/Danish dementia, familial encephalopathy, Amyotrophic lateral sclerosis/parkinsonism-dementia complex, Argyrophilic grain dementia, Corticobasal degeneration, Dementia pugilistica, diffuse neurofibrillary tangles with calcification, Down's syndrome, Gerstmann-Sträussler-Scheinker disease, Hallervorden-Spatz disease, Myotonic dystrophy, Niemann-Pick disease type C, Non-Guamanian motor neuron disease with neurofibrillary tangles, Pick's disease, Postencephalitic parkinsonism, Prion protein cerebral amyloid angiopathy, Progressive subcortical gliosis, Progressive supranuclear palsy, Subacute sclerosing panencephalitis, Tangle only dementia, frontotemporal lobar degenerations (FTLDs), and frontotemporal lobe dementia (FTD) including a patient having one or more of the following clinical syndromes: behavioral variant FTD (bvFTD), progressive non-fluent aphasia (PNFA), frontotemporal dementia with parkinsonism linked to chromosome 17, Progressive Supranuclear Palsey (PSP), and semantic dementia (SD).

20. The ~~method~~ use of claim 19, wherein the neurodegenerative disease is Parkinson's disease, Alzheimer's disease, or Huntington's disease.

21. The ~~method~~ use of claim 20, wherein the neurodegenerative disease is Alzheimer's disease.

22. The ~~method~~ use of claim 19, wherein the patient is suffering from a prion-mediated disease selected from Creutzfeldt-Jakob disease, kuru, fatal familial insomnia, ~~or~~ and Gerstmann-Sträussler-Scheinker syndrome.

23. A nucleic acid sequence encoding any one of the polypeptides of claims 1-12.

24. The nucleic acid sequence of claim 23 further encoding a mammalian signal sequence fused to and in frame with the polypeptide encoding sequence.

25. A vector comprising a nucleic acid sequence of claim 23 or 24, wherein the nucleic acid sequence is operatively linked to an expression control sequence in the vector.

26. A host cell containing the vector of claim 25.

27. A method of making a polypeptide of any one of claims 1-12 comprising the steps of expressing the protein encoded by the nucleic acid sequence of claim 23 or 24; and isolating the expressed polypeptide.